Ara
Toplam kayıt 3, listelenen: 1-3
Risk Assessment and Communication Tools For Genotype Associations With Multifactorial Phenotypes: The Concept of "Edge Effect" And Cultivating an Ethical Bridge Between Omics Innovations and Society
(Mary Ann Liebert, Inc, 2009)
Applications of omics technologies in the postgenomics era swiftly expanded from rare monogenic disorders to multifactorial common complex diseases, pharmacogenomics, and personalized medicine. Already, there are signposts ...
Bernard Lerer: Recipient of the 2014 Inaugural Werner Kalow Responsible Innovation Prize in Global Omics and Personalized Medicine (Pacific Rim Association For Clinical Pharmacogenetics)
(Mary Ann Liebert, Inc, 2014)
This article announces the recipient of the 2014 inaugural Werner Kalow Responsible Innovation Prize in Global Omics and Personalized Medicine by the Pacific Rim Association for Clinical Pharmacogenetics (PRACP): Bernard ...
An Appeal To The Global Health Community For A Tripartite Innovation: An "Essential Diagnostics List," "Health In All Policies," And "See-Through 21(St) Century Science And Ethics"
(Mary Ann Liebert, Inc, 2015)
Diagnostics spanning a wide range of new biotechnologies, including proteomics, metabolomics, and nanotechnology, are emerging as companion tests to innovative medicines. In this Opinion, we present the rationale for ...